Targeted Strategies for Today's Evolving Markets

MissionIR Blog

La Jolla Pharmaceutical Company (LJPC) Presents at Rodman & Renshaw Conference

La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development, including LJPC-501, the company’s proprietary formulation of angiotensin II, a naturally-occurring regulator of blood pressure, and LJPC-401, its novel formulation of hepcidin, an endogenous peptide hormone that controls and regulates iron metabolism. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.